Vilazodone

Summary

Vilazodone (CHEMBL439849) is an approved small-molecule antidepressant (ATC N06AX24) targeting HTR1A, DRD2, and DRD3; indicated across 4 conditions including depressive disorder and generalized anxiety disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX24
• Targets: 6 (HTR1A, DRD2, DRD3…)
• Indications: 4 conditions
• Clinical trials: 23
• Chemistry: 441.5 Da · C26H27N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL439849
Name	Vilazodone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6918314
ChEBI	CHEBI:70707
ATC	N06AX24
Molecular formula	C26H27N5O2
Molecular weight	441.5
InChIKey	SGEGOXDYSFKCPT-UHFFFAOYSA-N

SMILES: C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N

IUPAC name: 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide

ChEBI definition: A 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder.

Pharmacological roles (ChEBI): antidepressant, serotonergic agonist, serotonin uptake inhibitor.

Also known as: EMD 515259, EMD 68843 BASE, EMD-515259, Emd-68843 base, Vilazodona, Vilazodone, VILAZODONE, VILAZODONE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1615374

Patent coverage: 626 distinct patent families (1,555 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,291 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR1A	5-HT1A receptor	Partial agonist	9.52	0%	P08908
DRD2	D2 receptor	Agonist	6.18	0%	P14416
DRD3	D3 receptor	Agonist	7.15	0%	P35462
HRH1	H1 receptor	Agonist	6.5	0%	P35367
SLC6A4	SERT	Inhibition	9.3	0.7%	P31645
HTR4	5-HT4 receptor	Agonist	6.6	0%	Q13639

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: Serotonin 3 (5-HT3) receptor, Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, 5-hydroxytryptamine receptor 1A, Sodium-dependent serotonin transporter, D(3) dopamine receptor, 5-hydroxytryptamine receptor 7, Acetylcholinesterase, Acetylcholinesterase, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 2C, D(4) dopamine receptor, 5-hydroxytryptamine receptor 6.

Bioactivity

ChEMBL activities: 47 potent at pChembl ≥ 5 of 50 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	9.96	IC50	0.11	nM	CHEMBL_ACT_23295777
HTR1A	9.92	EC50	0.12	nM	CHEMBL_ACT_18291168
HTR1A	9.92	EC50	0.12	nM	CHEMBL_ACT_18996974
HTR1A	9.7	IC50	0.2	nM	CHEMBL_ACT_19114059
HTR1A	9.7	Ki	0.2	nM	CHEMBL_ACT_19283857
HTR1A	9.52	Ki	0.3	nM	CHEMBL_ACT_10913281
P19327	9.52	IC50	0.3	nM	CHEMBL_ACT_1467775
HTR1A	9.52	EC50	0.3	nM	CHEMBL_ACT_26120074
SLC6A4	9.4	IC50	0.4	nM	CHEMBL_ACT_18291221
SLC6A4	9.4	IC50	0.4	nM	CHEMBL_ACT_24416218
SLC6A4	9.4	IC50	0.4	nM	CHEMBL_ACT_24917639
SLC6A4	9.32	IC50	0.48	nM	CHEMBL_ACT_25447759
SLC6A4	9.3	Ki	0.5	nM	CHEMBL_ACT_10913304
P31652	9.3	IC50	0.5	nM	CHEMBL_ACT_1467788
P31652	9.3	IC50	0.5	nM	CHEMBL_ACT_19114067
P31652	9.3	IC50	0.5	nM	CHEMBL_ACT_19283888
P31652	9.3	IC50	0.5	nM	CHEMBL_ACT_26120075
P31652	9.17	IC50	0.67	nM	CHEMBL_ACT_23295744
SLC6A4	9.17	IC50	0.67	nM	CHEMBL_ACT_26120115
HTR1A	9.1	EC50	0.79	nM	CHEMBL_ACT_24416193
HTR1A	8.99	EC50	1.02	nM	CHEMBL_ACT_26120090
P31652	8.96	IC50	1.1	nM	CHEMBL_ACT_1466031
SLC6A4	8.72	Ki	1.9	nM	CHEMBL_ACT_18891579
P19327	8.36	IC50	4.4	nM	CHEMBL_ACT_1466030
HTR1A	8.01	Ki	9.7	nM	CHEMBL_ACT_18891608
P31652	7.6	IC50	25	nM	CHEMBL_ACT_24966874
HTR1A	7.55	Ki	28	nM	CHEMBL_ACT_24966879
P19020	7.15	IC50	71	nM	CHEMBL_ACT_1467668
P61169	7.02	IC50	95	nM	CHEMBL_ACT_1466032
SLC6A2	6.8	IC50	158.1	nM	CHEMBL_ACT_24416283
Q62758	6.6	IC50	252	nM	CHEMBL_ACT_1467785
SLC6A3	6.53	IC50	295	nM	CHEMBL_ACT_24416286
DRD2	6.18	Ki	666	nM	CHEMBL_ACT_10913396
P61169	6.18	IC50	666	nM	CHEMBL_ACT_1467667
P14842	5.82	IC50	1510	nM	CHEMBL_ACT_1467782
ADRA1D	5.7	IC50	1980	nM	CHEMBL_ACT_1467773
P08909	5.7	IC50	2000	nM	CHEMBL_ACT_1467783
P31388	5.52	IC50	3000	nM	CHEMBL_ACT_1467786
P32305	5.52	IC50	3000	nM	CHEMBL_ACT_1467787
P30729	5.47	IC50	3400	nM	CHEMBL_ACT_1467669
HTR7	5.41	Ki	3900	nM	CHEMBL_ACT_19283870
P28565	5.4	IC50	4000	nM	CHEMBL_ACT_1467780
P35563	5.37	IC50	4300	nM	CHEMBL_ACT_1467784
P28564	5.3	IC50	5000	nM	CHEMBL_ACT_1467666
KCNH2	5.26	IC50	5550	nM	CHEMBL_ACT_24416254
KCNH2	5.25	IC50	5600	nM	CHEMBL_ACT_24917700
ADRA2A	5.22	IC50	6000	nM	CHEMBL_ACT_1467774

Target pathways

Aggregated over 6 target gene(s): HTR1A, DRD2, DRD3, HRH1, SLC6A4, HTR4.

Top Reactome pathways

17 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	HTR1A, HTR4
Signaling by GPCR	2	HTR1A, HTR4
Class A/1 (Rhodopsin-like receptors)	2	HTR1A, HTR4
Amine ligand-binding receptors	2	HTR1A, HTR4
Dopamine receptors	2	DRD2, DRD3
Serotonin receptors	2	HTR1A, HTR4
GPCR ligand binding	2	HTR1A, HTR4
Neurotransmitter clearance	1	SLC6A4
Transmission across Chemical Synapses	1	SLC6A4
Neuronal System	1	SLC6A4
Serotonin clearance from the synaptic cleft	1	SLC6A4
GPCR downstream signalling	1	HTR4
Histamine receptors	1	HRH1
G alpha (q) signalling events	1	HRH1
G alpha (s) signalling events	1	HTR4
G alpha (i) signalling events	1	DRD3
SLC-mediated transport of neurotransmitters	1	SLC6A4

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	5
signal transduction	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	3
chemical synaptic transmission	3
visual learning	3
response to xenobiotic stimulus	3
behavioral response to cocaine	3
adenylate cyclase-inhibiting serotonin receptor signaling pathway	2
adult behavior	2
adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
G protein-coupled serotonin receptor signaling pathway	2
response to hypoxia	2
G protein-coupled receptor internalization	2
intracellular calcium ion homeostasis	2
adenylate cyclase-inhibiting dopamine receptor signaling pathway	2

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
generalized anxiety disorder	3	MONDO:0001942	EFO:1001892
cannabis dependence	2	MONDO:0005689	EFO:0007191

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE3	9
PHASE4	6
PHASE2	4
Not specified	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01473381	PHASE4	COMPLETED	Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01473394	PHASE4	COMPLETED	Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
NCT01573598	PHASE4	COMPLETED	Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01856127	PHASE4	TERMINATED	Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?
NCT01999920	PHASE4	COMPLETED	Vilazodone for Separation Anxiety Disorder
NCT02028026	PHASE4	WITHDRAWN	The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
NCT00285376	PHASE3	COMPLETED	Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
NCT00644358	PHASE3	COMPLETED	A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
NCT00683592	PHASE3	COMPLETED	Randomized, Double-Blind, Placebo Controlled Study of Vilazodone’s Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
NCT01629966	PHASE3	COMPLETED	Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
NCT01844115	PHASE3	COMPLETED	Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
NCT01878292	PHASE3	COMPLETED	Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
NCT02015546	PHASE3	COMPLETED	Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
NCT02372799	PHASE3	COMPLETED	Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
NCT02436239	PHASE3	COMPLETED	A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
NCT00290914	PHASE2	COMPLETED	Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
NCT01574183	PHASE2	COMPLETED	Vilazodone Treatment for Marijuana Dependence
NCT01742832	PHASE2	COMPLETED	Double-Blind Treatment of Major Depressive Disorder With Vilazodone
NCT01828515	PHASE2	COMPLETED	Vilazodone for Corticosteroid-Induced Memory Impairment
NCT02097147	PHASE1	COMPLETED	Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo
NCT01680900	Not specified	COMPLETED	Vilazodone for Menopausal Hot Flashes
NCT01712321	Not specified	UNKNOWN	Study of Vilazodone to Treat Social Anxiety Disorder
NCT02893371	Not specified	TERMINATED	Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

847 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4
HALOPERIDOL	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4
CISAPRIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR4, SLC6A4
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
APOMORPHINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ASENAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
BROMPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CABERGOLINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CINNARIZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CLEMASTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CLOZAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
DIBENZEPIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
DOMPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
DULOXETINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
EBASTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
EPALRESTAT	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
OLANZAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PERPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PRENYLAMINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PROMETHAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
RISPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ROTIGOTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
SERTINDOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
SERTRALINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
SUNITINIB	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
TERFENADINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
THIETHYLPERAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
THIORIDAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
TRAZODONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
TRIFLUOPERAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, SLC6A4
MELITRACEN	ChEMBL	Phase 3	DRD2, DRD3, HRH1, HTR1A, SLC6A4
OPIPRAMOL	ChEMBL	Phase 3	DRD2, DRD3, HRH1, HTR1A, SLC6A4
OTILONIUM BROMIDE	ChEMBL	Phase 3	DRD2, DRD3, HRH1, HTR1A, SLC6A4
URAPIDIL	ChEMBL	Phase 3	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ZUCLOPENTHIXOL	ChEMBL	Phase 3	DRD2, DRD3, HRH1, HTR1A, SLC6A4
AMOSULALOL	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
BENZETHONIUM	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
CLOTHIAPINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
DOMIPHEN	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
FANANSERIN	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
FLUNARIZINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
IFENPRODIL	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
MEQUITAZINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
METERGOLINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
NEMONAPRIDE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
NIGULDIPINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PENFLURIDOL	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
PIZOTYLINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
RITANSERIN	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
SPIPERONE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
SPIRAMIDE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
THIOPROPERAZINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
ZOTEPINE	ChEMBL	Phase 2	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Afatinib	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Apixaban	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Binimetinib	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Bosentan	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
chenodiol	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Fidaxomicin	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Fulvestrant	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Imipenem	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Linagliptin	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Propoxyphene	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
Pyrazinamide	PubChem	Approved	DRD2, DRD3, HRH1, HTR1A, SLC6A4
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HTR1A, SLC6A4
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	DRD3, HRH1, HTR1A, SLC6A4
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A
AMIODARONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, SLC6A4
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, SLC6A4